RxDoctor Payments Data

Connie Pham, DO

Family Medicine · Costa Mesa, CANPI 1073967584

Payments from drug & device makers

$2,214in general payments, 2019–2025

Across 84 payments — averaging $26.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$523
  • Teva Pharmaceuticals USA, Inc.$267
  • GSK$207
  • Amgen$189
  • AbbVie$156
  • Pfizer$141
  • plus $731 from 10 others

What the payments were for

  • Food & beverage$2,214100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,214 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$45,349
Medicare patients
143
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$71,969
OzempicSemaglutide43$57,961
JardianceEmpagliflozin16$28,831
UbrelvyUbrogepant13$20,688
EliquisApixaban12$20,314
FarxigaDapagliflozin Propanediol14$16,547
Gabapentin85$1,740
Albuterol Sulfate HfaAlbuterol Sulfate64$1,540
Pregabalin17$1,491
Atorvastatin Calcium145$1,414
Losartan Potassium139$1,360
Azelastine Hcl41$1,139
Levothyroxine Sodium118$1,131
Bupropion XlBupropion Hcl38$877
Fluticasone Propionate77$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$117$71,96954 claims
Novo NordiskOzempic$134$57,96143 claims
Boehringer IngelheimJardiance$68$28,83116 claims
AbbVieUbrelvy$156$20,68813 claims
PfizerEliquis$141$20,31412 claims
AstraZenecaFarxiga$523$16,54714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Costa Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →